• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BioNTech SE (Amendment)

    2/14/24 7:26:25 AM ET
    $BNTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BNTX alert in real time by email
    SC 13G/A 1 d754017dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)* 

     

     

    BIONTECH SE

    (Name of Issuer)

    Ordinary Shares, no par value per share (€1.00 nominal amount)

    (including Ordinary Shares represented by American Depositary Shares)

    (Title of Class of Securities)

    09075V102**

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    **

    This CUSIP number applies to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol “BNTX.” Each ADS represents one Ordinary Share. No CUSIP has been assigned to the Ordinary Shares.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    SCHEDULE 13G

    CUSIP No. 09075V102

     

     1   

     NAME OF REPORTING PERSONS

     

     Medine GmbH

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Germany

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     0

       6   

     SHARED VOTING POWER

     

     39,111,390

       7   

     SOLE DISPOSITIVE POWER

     

     0

       8   

     SHARED DISPOSITIVE POWER

     

     39,111,390

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     40,439,542(1)

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     17.0%

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     OO

     

    (1) 

    Consists of 39,111,390 ordinary shares held by Medine GmbH and 1,328,152 ordinary shares held by a former colleague, over which shares Prof. Ugur Sahin, M.D. retains voting power pursuant to a written arrangement. Pursuant to this arrangement, Prof. Ugur Sahin, M.D. retains voting power, but not dispositive power, over such shares, and accordingly Medine GmbH and Prof. Ugur Sahin, M.D. each may be deemed beneficially to own such shares. Since the time of the initial filing on Schedule 13G by Medine GmbH and Prof. Ugur Sahin, M.D. on February 13, 2020, 1,251,428 shares previously held by Medine GmbH or colleagues pursuant to this and similar arrangements with colleagues have been transferred to, or disposed of by, the respective beneficiaries, and accordingly neither Medine GmbH nor Prof. Ugur Sahin, M.D. remain a beneficial owner of such shares. Neither Medine GmbH nor Prof. Ugur Sahin, M.D. has sold any ordinary shares or ADSs since the initial filing on Schedule 13G by such persons on February 13, 2020.


    SCHEDULE 13G

    CUSIP No. 09075V102

     

     1   

     NAME OF REPORTING PERSONS

     

     Prof. Ugur Sahin, M.D.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Turkey

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     856,186

       6   

     SHARED VOTING POWER

     

     40,439,542(2)

       7   

     SOLE DISPOSITIVE POWER

     

     856,186

       8   

     SHARED DISPOSITIVE POWER

     

     39,111,390

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     41,295,728

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     17.4%

    12  

     TYPE OF REPORTING PERSON (See Instructions)

     

     IN

     

    (2) 

    Consists of 39,111,390 ordinary shares held by Medine GmbH and 1,328,152 ordinary shares held by a former colleague, over which shares Prof. Ugur Sahin, M.D. retains voting power pursuant to a written arrangement. Pursuant to this arrangement, Prof. Ugur Sahin, M.D. retains voting power, but not dispositive power, over such shares, and accordingly Medine GmbH and Prof. Ugur Sahin, M.D. each may be deemed beneficially to own such shares. Since the time of the initial filing on Schedule 13G by Medine GmbH and Prof. Ugur Sahin, M.D. on February 13, 2020, 1,251,428 shares previously held by Medine GmbH or colleagues pursuant to this and similar arrangements with colleagues have been transferred to, or disposed of by, the respective beneficiaries, and accordingly neither Medine GmbH nor Prof. Ugur Sahin, M.D. remain a beneficial owner of such shares. Neither Medine GmbH nor Prof. Ugur Sahin, M.D. has sold any ordinary shares or ADSs since the initial filing on Schedule 13G by such persons on February 13, 2020.


    Item 1(a)

    Name of Issuer.

    The name of the issuer is BioNTech SE (the “Issuer”).

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices.

    The Issuer’s principal executive office is located at An der Goldgrube 12, D-55131 Mainz, Germany.

     

    Item 2(a)

    Name of Person Filing.

    This Amendment No. 4 to Schedule 13G is being jointly filed by Medine GmbH and Prof. Ugur Sahin, M.D., each of the foregoing, a “Reporting Person,” and together, the “Reporting Persons”.

    The Reporting Persons have entered into a Joint Filing Agreement, dated February 13, 2020, a copy of which is incorporated by reference herein to Exhibit on the Schedule 13G filed on February 13, 2020, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.

     

    Item 2(b)

    Address of Principal Business Office or, if none, Residence.

    The address of the principal business office of each of the Reporting Persons is Philipp-von-Zabern-Platz 1, D-55116 Mainz, Germany.

     

    Item 2(c)

    Citizenship.

    Medine GmbH is a German limited liability company (Gesellschaft mit beschränkter Haftung). Prof. Ugur Sahin, M.D. is a citizen of Turkey.

     

    Item 2(d)

    Title of Class of Securities.

    Ordinary Shares, no par value per share (€1.00 nominal amount) (including Ordinary Shares represented by American Depositary Shares).

     

    Item 2(e)

    CUSIP No.

    09075V102 (This CUSIP number applies to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol “BNTX.” Each ADS represents one Ordinary Share. No CUSIP has been assigned to the Ordinary Shares.)

     

    Item 3

    If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), check whether the person filing is a:

    Not applicable.


    Item 4

    Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)   

    Amount beneficially owned:

       See the responses to Item 9 on the attached cover pages.
    (b)   

    Percent of class:

       See the responses to Item 11 on the attached cover pages, which were calculated based on 237,715,500 ordinary shares of the Issuer outstanding as of September 30, 2023, as reported by the Issuer in its Form 6-K filed with the Securities and Exchange Commission on November 6, 2023.
    (c)   

    Number of shares as to which such person has:

      
      

    (i) Sole power to vote or direct the vote:

       See the responses to Item 5 on the attached cover pages.
      

    (ii)  Shared power to vote or direct the vote:

       See the responses to Item 6 on the attached cover pages.
      

    (iii)  Sole power to dispose or direct the disposition:

       See the responses to Item 7 on the attached cover pages.
      

    (iv) Shared power to dispose or direct the disposition:

       See the responses to Item 8 on the attached cover pages.

     

    Item 5

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6

    Ownership of More Than Five Percent on Behalf of Another Person.

    See responses to Item 2(a) and Item 4.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    See responses to Item 2(a) and Item 4.

     

    Item 8

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10

    Certifications.

    Not applicable.


    SIGNATURE

    After reasonable inquiry and to the best of each of the undersigned’s knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2024     MEDINE GMBH
        By:  

    /s/ Prof. Ugur Sahin, M.D.

        Name: Prof. Ugur Sahin, M.D.
        Title: Authorized Signatory
    Date: February 14, 2024     PROF. UGUR SAHIN, M.D.
       

    /s/ Prof. Ugur Sahin, M.D.

    Get the next $BNTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BNTX

    DatePrice TargetRatingAnalyst
    3/13/2025$145.00Buy
    Citigroup
    1/10/2025$172.00Buy
    Truist
    12/11/2024$170.00Overweight
    Wells Fargo
    12/2/2024Outperform
    BMO Capital Markets
    11/19/2024$130.00Buy
    Berenberg
    11/19/2024$110.00 → $125.00In-line → Outperform
    Evercore ISI
    11/8/2024$90.00 → $137.00Neutral → Buy
    Goldman
    9/24/2024$93.00 → $145.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $BNTX
    Financials

    Live finance-specific insights

    See more
    • BioNTech Announces First Quarter 2025 Financial Results and Corporate Update

      Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA cancer immunotherapies Presented multiple clinical updates across oncology pipeline underlining BioNTech's combination strategy in oncology with first data presented for the novel combination of BNT327 plus antibody-drug conjugates ("ADCs") Development and commercial preparation for a 2025/2026 season variant-adapted COVID-19 vaccine First quarter 2025 revenues of €0.2 billion2, net loss of €0.4 billion and basic and diluted loss per share of €1.73 ($1.823) Maintained strong financial positio

      5/5/25 6:45:00 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025

      MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via thi

      4/22/25 6:45:00 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update

      Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator candidate BNT327 and mRNA cancer immunotherapies Multiple data readouts expected in 2025 and 2026 aimed at providing clinical proof of BioNTech's pipeline strategy and advancing the Company towards becoming a diversified multi-product oncology portfolio company by 2030 Completed acquisition of Biotheus securing full control of next-generation immunomodulator candidate BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1 Successfully launched JN.1- and KP.2-adapted COVID-19 vaccines across different coun

      3/10/25 6:55:00 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BNTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Citigroup initiated coverage on BioNTech with a new price target

      Citigroup initiated coverage of BioNTech with a rating of Buy and set a new price target of $145.00

      3/13/25 7:26:20 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Truist initiated coverage on BioNTech with a new price target

      Truist initiated coverage of BioNTech with a rating of Buy and set a new price target of $172.00

      1/10/25 7:35:55 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wells Fargo initiated coverage on BioNTech with a new price target

      Wells Fargo initiated coverage of BioNTech with a rating of Overweight and set a new price target of $170.00

      12/11/24 7:26:08 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BNTX
    Leadership Updates

    Live Leadership Updates

    See more
    • BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer

      Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer ("CFO") effective July 1, 2025. He will join BioNTech from Novartis AG's global biomedical research organization where he has been serving as CFO since 2022. Ramón Zapata will succeed Jens Holstein, who, as previously planned and announced, will retire at the end of his term on June 30, 2025. In his new role as CFO at BioNTech, Ramón Zapata will ensure the Company's financial direction continues to align with BioNTech's strategy to become a multi-product company i

      5/5/25 6:30:00 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioNTech to Acquire Biotheus to Boost Oncology Strategy

      Acquisition to support the global execution of BioNTech's oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumorsWith the acquisition of Biotheus, BioNTech aims to further strengthen its capabilities to develop, manufacture and commercialize next-generation bispecific antibodies and novel treatment combinationsBioNTech and Biotheus plan to initiate multiple registrational trials with BNT327/PM8002 in late 2024 and 2025; further clinical trials evaluating BNT327/PM8002 as combination therapies are planned to start in 2024 and 202

      11/13/24 6:45:00 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioNTech to Host Innovation Series R&D Day on November 14, 2024

      MAINZ, Germany, October 31, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")), will host an edition of the Company's Innovation Series R&D Day at 10:30 a.m. Eastern Standard Time (16:30 p.m. CET) on Thursday, November 14, 2024 in New York City, U.S. On the day, BioNTech's leadership team will provide an overview of the Company's corporate strategy and clinical progress across its pipeline. Investors, analysts and the interested public are invited to join the event online via this link. A replay of the webcast will be available shortly after the conclusion of the event and archived on the Company's website for one yea

      10/31/24 7:45:00 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BNTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by BioNTech SE

      SC 13G/A - BioNTech SE (0001776985) (Subject)

      11/13/24 5:00:57 PM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D filed by BioNTech SE

      SC 13D - BioNTech SE (0001776985) (Filed by)

      2/21/24 5:01:33 PM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by BioNTech SE (Amendment)

      SC 13G/A - BioNTech SE (0001776985) (Subject)

      2/14/24 7:26:25 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BNTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioNTech Announces First Quarter 2025 Financial Results and Corporate Update

      Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA cancer immunotherapies Presented multiple clinical updates across oncology pipeline underlining BioNTech's combination strategy in oncology with first data presented for the novel combination of BNT327 plus antibody-drug conjugates ("ADCs") Development and commercial preparation for a 2025/2026 season variant-adapted COVID-19 vaccine First quarter 2025 revenues of €0.2 billion2, net loss of €0.4 billion and basic and diluted loss per share of €1.73 ($1.823) Maintained strong financial positio

      5/5/25 6:45:00 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer

      Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer ("CFO") effective July 1, 2025. He will join BioNTech from Novartis AG's global biomedical research organization where he has been serving as CFO since 2022. Ramón Zapata will succeed Jens Holstein, who, as previously planned and announced, will retire at the end of his term on June 30, 2025. In his new role as CFO at BioNTech, Ramón Zapata will ensure the Company's financial direction continues to align with BioNTech's strategy to become a multi-product company i

      5/5/25 6:30:00 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025

      MAINZ, Germany, April 24, 2025 -- BioNTech SE (NASDAQ:BNTX, "BioNTech" or "the Company")) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, at the American Association for Cancer Research ("AACR") Annual Meeting held in Chicago, Illinois from April 25-30, 2025. The oral and poster presentations underline both the progress of BioNTech's advanced priority oncology programs as well as the execution of the Company's combination strategy in oncology, with first data to be presented for the combination of the PD-L1xVEGF-A bispecific antibody candidate BNT3271 plus antibody-d

      4/24/25 6:45:00 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BNTX
    SEC Filings

    See more
    • SEC Form 6-K filed by BioNTech SE

      6-K - BioNTech SE (0001776985) (Filer)

      5/5/25 7:33:14 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by BioNTech SE

      6-K - BioNTech SE (0001776985) (Filer)

      5/5/25 6:53:42 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by BioNTech SE

      6-K - BioNTech SE (0001776985) (Filer)

      5/5/25 6:33:52 AM ET
      $BNTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care